The role of Tadalafil in the treatment of benign prostatic hyperplasia and erectile dysfunction

M.G. Arikan; O. Atacer; I. Yuksel; E. Arda; B. Cakiroglu; M. Cek

doi:10.26641/2307-5279.26.1.2022.260490

Authors

M.G. Arikan Edirne Sultan I. Murat State Hospital, Turkey https://orcid.org/0000-0002-9707-596X
O. Atacer Trakya University School of Medicine, Turkey https://orcid.org/0000-0003-0512-0768
I. Yuksel Private Kesan Hospital, Turkey https://orcid.org/0000-0002-6902-8170
E. Arda Trakya University School of Medicine, Turkey https://orcid.org/0000-0002-5430-6561
B. Cakiroglu Istanbul Hisar Intercontinental Hospital, Turkey https://orcid.org/0000-0001-5337-5226
M. Cek Trakya University School of Medicine, Turkey https://orcid.org/0000-0003-1367-7224

DOI:

https://doi.org/10.26641/2307-5279.26.1.2022.260490

Abstract

The aim of this study is to investigate the effectiveness of a single 5 mg daily dose of Tadalafil in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) accompanied by erectile dysfunction (ED). The data of patients who applied to the urology outpatient clinic between 2014 and 2019 and were diagnosed with BPH and ED were retrospectively analysed. Before and after the treatment with 5 mg tadalafil daily for 12 weeks; maximum flow rate (Qmax), average flow rate (Qave), postvoid residual volume (PVR), prostate volume (PV), PSA values, IPSS and IIEF scores of the patients were compared. The mean age of 66 male patients diagnosed with ED and BPH was 48.1±6.9 years. The mean IPSS score of the patients before the treatment was 9.85 which represents moderate LUTS. After the treatment, the mean score decreased to 5.7 which represents mild LUTS. Before the treatment, the mean IIEF score showed mild ED with 18.79. After the treatment, the mean IIEF score increased to 29,9. The treatment statistically significantly decreased ED and increased the IIEF score (p=0.000). While the mean Qmax and Qave were increased statistically significantly (p=0.000). A statistically significant decrease was observed in the mean PVR from 60.1 ml to 37.6 ml (p=0.000). The decrease in PV was not statistically significant (p=0.321). The decrease in PSA values before and after treatment was found to be statistically significant with p=0.046. It has been shown that the daily use of 5 mg Tadalafil alone for 12 weeks can be a preferable treatment option, especially in younger patients with BPH / LUTS and ED.

References

Gacci M., Eardley I., Giuliano F., Hatzichristou D., Kaplan S.A., Maggi M. et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011. 60(4). 809–825. Doi: 10.1016/j.eururo.2011.06.037.

McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole G.L. Jr., Dixon C.M., Kusek J.W. et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003. 349(25). 2387–98. Doi: 10.1056/NEJMoa030656.

Oelke M., Bachmann A., Descazeaud A., Emberton M., Gravas S., Michel M.C. et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013. 64(1). 118–140. Doi: 10.1016/j.eururo. 2013.03.004.

Morelli A., Sarchielli E., Comeglio P., Filippi S,. Mancina R., Gacci M. et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med. 2011. 8(10). 2746–2760. Doi: 10.1111/j.1743-6109.2011.02416.x.

Andersson K.E., de Groat W.C., McVary K.T., Lue T.F., Maggi M., Roehrborn C.G. et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011. 30(3). 292–301. Doi: 10.1002/nau.20999.

McVary K.T., Monnig W., Camps J.L. Jr., Young J.M., Tseng L.J., van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007. 177(3). 1071–1077. Doi: 10.1016/j.juro.2006.10.055.

Stief C.G., Porst H., Neuser D., Beneke M., Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008. 53(6). 1236–1244. Doi:10.1016/j.eururo. 2008.01.075.

Egerdie R.B., Auerbach S., Roehrborn C.G., Costa P., Garza M.S., Esler A.L. et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med. 2012. 9(1). 271–281. Doi: 10.1111/j.1743-6109.2011.02504.x.

Wang Y., Bao Y., Liu J., Duan L., Cui Y. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. Low Urin Tract Symptoms. 2018. 10(1). 84–92. Doi:10.1111/luts.12144.

Oelke M., Giuliano F., Mirone V., Xu L., Cox D., Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012. 61(5). 917–925. Doi:10.1016/j.eururo.2012.01.013.

Roehrborn C.G., Egan K.B., Miner M.M., Ni X., Wong D.G., Rosen R.C. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment. BJU Int. 2016. 118(1). 153–160. Doi: 10.1111/bju.13406.

Porst H., McVary K.T., Montorsi F., Sutherland P., Elion-Mboussa A., Wolka A.M. et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol. 2009. 56(4). 727–735. Doi: 10.1016/j.eururo. 2009.04.033.

Roehrborn C.G., McVary K.T., Elion- Mboussa A., Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008. 180(4). 1228–1234. Doi: 10.1016/j.juro.2008.06.079.

Chapple C.R., Roehrborn C.G., McVary K., Ilo D., Henneges C., Viktrup L. Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials. Eur Urol. 2015. 67(1). 114–122. Doi: 10.1016/j.eururo.2014.08.072.

Morelli A., Filippi S., Sandner P., Fibbi B., Chavalmane A.K., Silvestrini E. et al. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med. 2009. 6(6). 1594–1608. Doi: 10.1111/j.1743-6109.2009.01249.x.

Gacci M., Corona G., Salvi M., Vignozzi L., McVary K.T., Kaplan S.A. et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012. 61(5). 994–1003. Doi: 10.1016/j.eururo.2012.02.033.

Roehrborn C.G., Kaminetsky J.C., Auerbach S.M., Montelongo R.M., Elion-Mboussa A., Viktrup L. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int. 2010. 105(4). 502–507. Doi: 10.1111/j.1464-410X.2009.08822.x.

Takahashi R., Miyazato M., Nishii H., Sumino Y., Takayama K., Onzuka M. et al. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study). Low Urin Tract Symptoms. 2018. 10(1). 76–83. Doi: 10.1111/luts.12143.

Rosen R., Altwein J., Boyle P., Kirby R.S., Lukacs B., Meuleman E. et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003. 44(6). 637–649. Doi: 10.1016/j.eururo.2003.08.015.

Pinggera G.M., Frauscher F., Paduch D.A., Bolyakov A., Efros M., Kaminetsky J. et al. Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial. Urology. 2014. 84(2). 412–419. Doi:10.1016/j.urology.2014.02.063.

Arreola-Ornelas H.G.-M.L., Rosado Buzzo A., Mould-Quevedo J., Dбvila-Loaiza G. Savings through sildenafil use as a coadjuvant in parmacological treatment adherence in hypertension and type 2 diabetes in Mexico. Rev Mex Urol. 2008. 68. 21–35.

Hansen S.A., Aas E., Solli O. A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction. Eur J Health Econ. 2020. 21(1). 73–84. Doi: 10.1007/s10198-019-01112-8.

The role of Tadalafil in the treatment of benign prostatic hyperplasia and erectile dysfunction

Authors

DOI:

Abstract

References

Downloads

Published

Issue

Section

License

Developed By